JP Morgan Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Target of $135
JP Morgan analyst Brian Cheng initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Overweight rating and announces Price Target of $135.
Share
Why It Matters
A big bank analyst started following Dianthus and said the company looks good to them. When smart money watchers get excited about a small company, it can mean they see something special worth paying attention to.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.